76 results about "Osteopontin" patented technology

The invention discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. According to the invention, the 1, 3-dioleic acid-2-palmitin, the osteopontin and the oligosaccharide are compounded for use, and the components interact to promote mutual absorption and utilization, so that the growth and development of bones in the growth period of infants are improved, the mineral content and the bone mineral density of the bones are increased, the health of the bones is promoted, and the composition is safe and free of side effects. And by optimizing the variety of the oligosaccharide, the compound use of the galactooligosaccharide and the 2 '-fucosyllactose is found to be capable of better improving the growth and development of bones in the growth period of the infants.

The invention provides a composition for promoting bone health and bone formation as well as application and a product thereof, and belongs to the field of foods. The composition disclosed by the invention is prepared from the following components in parts by weight: 1 to 5 parts of osteopontin, 1 to 50 parts of 2 '-fucosyllactose and 0.05 to 50 parts of a calcium source. The composition disclosed by the invention shows a relatively good synergistic effect in promoting calcium absorption, and can be used for improving bone density, preventing and treating osteoporosis and the like.

The invention provides a nutrition enhancer beneficial to bone health of middle-aged and elderly people, a preparation method of the nutrition enhancer and application of the nutrition enhancer in preparation of medial care food, and belongs to the field of nutritious food. The nutrient supplement comprises a plant fermentation product, osteopontin peptide, collagen peptide, N-acetylglucosamine and calcium, vitamins and mineral substances can be added, and the plant fermentation product is obtained by performing anaerobic fermentation on rhizoma drynariae and chestnuts through a complex microbial inoculant composed of lactobacillus reuteri and bifidobacterium longum subsp. Longum; the collagen peptide is prepared by performing enzymolysis on bovine bones through alkaline protease and flavourzyme; the hydrogel is prepared by adopting a sodium alginate-calcium chloride-carboxymethyl chitosan micro-capsule embedding process. An in-vitro experiment shows that the nutrition enhancer can remarkably promote osteoblast proliferation, differentiation and mineralization; animal experiments show that the bone mineral density of osteoporosis model mice can be effectively improved. The nutrition enhancer disclosed by the invention is suitable for preparing care food and bone health products, and has a remarkable effect of improving bone health of middle-aged and elderly people.

The invention belongs to the field of nutrient substance research, and particularly relates to a nutrient composition and application thereof. The nutritional composition provided by the invention comprises the following two necessary components: i) osteopontin and ii) hyaluronic acid or salt thereof, and in the nutritional composition, the mass ratio of the i) osteopontin to the ii) hyaluronic acid or salt thereof is 1: (0.05-10). Research finds that compared with osteopontin monomers or hyaluronic acid or salt monomers thereof, after osteopontin and hyaluronic acid or salt thereof are combined according to a certain proportion, the osteopontin and the hyaluronic acid or salt thereof have a synergistic effect of regulating brain immunity.

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.

The invention provides infant formula milk powder for improving intestinal inflammation and recovering key flora as well as a preparation method and application of the infant formula milk powder. The invention firstly provides the infant formula milk powder, the infant formula milk powder comprises 2 '-fucosyllactose and osteopontin, the mass ratio of the 2'-fucosyllactose to the osteopontin is 1: (0.017-1.3), and every 100 g of the infant formula milk powder comprises 8-24 g of protein, 14-31 g of fat, 0.83-7.6 g of dietary fiber and 50-61 g of carbohydrate. The infant formula milk powder can improve intestinal inflammation and recover key flora.

The application discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. The composition is prepared by using 1,3-dioleic acid-2-palmitic acid triglyceride, osteonectin and oligosaccharide in combination, and through the interaction between the components, the absorption and utilization of each other are promoted, the growth and development of the bone of an infant in the growth period are improved, the bone mineral content and bone density are improved, the bone health is promoted, and the composition is safe and has no side effect. Through optimization of the types of the oligosaccharide, it is found that the combination of oligogalactose and 2'-fucosyllactose can better improve the growth and development of the bone of the infant in the growth period.

The invention belongs to the technical field of pharmaceutical compositions, and particularly relates to a composition helpful for improving bone mineral density and application thereof. The composition comprises sheep milk casein peptide, collagen tripeptide, sea cucumber peptide and osteopontin, can achieve the effects of improving bone mineral density and preventing and treating osteoporosis, integrates functionality and nutrition, and has wide application prospects in the aspect of promoting calcium absorption.

The invention discloses a preparation technology of a lactoferrin and osteopontin compound capable of improving bone health, and belongs to the technical field of food processing. In the compound, the mass ratio of lactoferrin to osteopontin is (3-5): 1, and the pH is 4-5.5. In a zebra fish model, after intervention of the lactoferrin, the osteopontin, the compound or the mixture, compared with a mixture group, the compound group of the lactoferrin and the osteopontin can obviously improve the fluorescence intensity of zebra fish spines, the relative bone mineral density is improved by 31.12%, and compared with a blank group, the relative bone mineral density is improved by 2.39 times. Therefore, the lactoferrin and osteopontin compound with the function of improving bone health can be prepared, and the lactoferrin and osteopontin compound has good application potential.

The present invention discloses an inducer, macrophages, and their applications, relating to the interdisciplinary fields of immunology, cell biology, and regenerative medicine. The invention utilizes a composition composed of osteopontin (OPN) and other cytokines to culture and induce monocytes, thereby generating macrophages with strong repair functions. These macrophages can be used to repair tissue wounds, promoting the healing and tissue regeneration of chronic, difficult-to-heal wounds, and exhibiting excellent repair effects, making them suitable for widespread application.

The present invention discloses a method for establishing porcine osteopontin IC-ELISA detection, a kit and an application thereof, and belongs to the technical field of immunology. The osteopontin enzyme-linked immunosorbent assay kit and method provided by the present invention can detect the content of osteopontin in semen; the specificity is good, the sensitivity is high, the accuracy of the test results is good, and the repeatability is good; the sample processing is simple, the test operation is simple, and the kit is provided in the form of a working solution, which can be used to screen large-scale boar populations in pig farms.

The invention relates to the technical field of biology, in particular to application of osteopontin in regulation of intestinal anaerobic symbiotic bacteria colonization. The osteopontin is used for preparing food or medicine for improving the immunity of the intestinal tract, and the food or medicine is used for improving the abundance of anaerobic symbiotic bacteria in the intestinal tract; according to the application disclosed by the invention, firstly, by virtue of transcriptome analysis, it is proved that the abundance of Parabacteroids distans and Blautiapseudococcoids can be remarkably improved by virtue of the exogenous osteopontin, so that the abundance of the Parabacteroids distans and the abundance of the Blautiapseudococcoids can be remarkably improved; secondly, the invention also proves that the exogenous osteopontin can be used for inhibiting the proliferation of harmful bacteria Escherichia coli; therefore, the intestinal immunity is improved, the intestinal barrier is improved or repaired, and the intestinal flora balance is maintained. The composition is suitable for infants, old people, patients and other people with low immunity.

The disclosed invention provides mammalian milk osteopontin and / or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and / or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and / or an active truncation thereof.

The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

The present invention relates to the use of urine protein as a diagnostic marker for primary biliary cholangitis (PBC). The urine protein includes one or a combination of osteopontin (OPN), receptor activity-modifying protein 3 (RAMP3), and calcium-binding protein (S100A8). This application uses urine as a non-invasive test sample, making it more readily accepted by patients than blood. It is of great significance for the early, non-invasive diagnosis of PBC patients.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody / antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.

The application provides a composition for promoting bone health and bone formation, and application and products thereof, and belongs to the field of food. The composition of the application is composed of 2'-fucosyllactose, osteopontin and a calcium source, wherein the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight. The composition of the application shows a good synergistic effect in promoting calcium absorption, and can be used for increasing bone density, preventing and treating osteoporosis and the like.

The invention provides a children formula food for improving intestinal inflammation and recovering key flora as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or children formula food, the infant formula food comprises 2 '-fucosyllactose and osteopontin, and the mass ratio of the 2'-fucosyllactose to the osteopontin is 1: (0.017-1.3). The children formula food disclosed by the invention can improve intestinal inflammation and recover key flora.

The invention belongs to the technical field of food and medicine, and particularly relates to a protein compound for relieving intestinal inflammation and a preparation method and application thereof. The protein compound for relieving intestinal inflammation provided by the invention is mainly prepared by compounding milk-derived osteopontin (OPN) and alpha-lactalbumin (alpha-LA). Compared with single OPN or alpha-LA, the protein complex provided by the invention shows a remarkable effect of promoting proliferation of intestinal epithelial cells, and effectively improves the physical barrier function of intestinal tracts and relieves intestinal inflammation damage caused by lipopolysaccharide by enhancing expression of tight junction protein. Therefore, the invention proves that the OPN-alpha-LA compound has a remarkable effect of relieving intestinal inflammation, which not only is beneficial to promoting the in-depth study of OPN and the compound thereof in regulating intestinal mucosal immunity in the functional protein field, but also can lay a scientific foundation for developing novel functional foods or novel enteritis medicines by using the active protein as a raw material.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

The present invention relates to a combination comprising osteopontin and lactoferrin in effective amount for use in promoting social-emotional development in a young individual. The present invention further relates to compositions and methods for promoting social-emotional development in a young individual, preferably in an infant.

The invention discloses a Lactobacillus paracasei strain capable of relieving bone resorption and having an anti-inflammatory effect and a metagen thereof, and belongs to the technical field of microorganisms. The invention provides a novel application of the Lactobacillus paracasei CCFM1396 (Lactobacillus paracasei CCFM1396) in the treatment of the orthodontically induced excessive bone resorption, and particularly provides the application of the Lactobacillus paracasei CCFM1396 in the treatment of the orthodontically induced excessive bone resorption. The lactobacillus paracasei provided by the invention can regulate and control osteoblasts to secrete osteoprotegerin (OPG) and improve gene expression of bone morphogenetic protein (BMP), osteoprotegerin (OPG) and osteopontin (OPN). In a rat orthodontic model, the strain disclosed by the invention can effectively relieve bone resorption, inhibit the inflammatory factor level of gingival tissues and protect the stability of periodontal tissues.

The present invention relates to a complex coacervate comprising lactoferrin and osteopontin, processes of producing the same and composition comprising the same. Moreover, the present invention relates to complexes comprising lactoferrin and osteo-pontin in the treatment and / or prevention of metabolic diseases and / or inflammatory diseases. Moreover, the present invention relates to complexes comprising lactoferrin and osteopontin for promoting bone development, growth, strength and / or healing, or preventing and / or treating a bone disease.

The present invention relates to the technical field of intestinal flora regulation, in particular to the application of osteopontin in intestinal flora homeostasis regulation; the technical problem to be solved by the present invention is to provide the use of osteopontin in regulating the homeostasis balance of mammalian intestinal flora; the present invention expects to increase the abundance of intestinal probiotics or reduce the abundance of harmful bacteria through the intake or expression of osteopontin; the abundance of probiotics or symbiotic bacteria including Akkermansia muciniphila in the intestine is increased by osteopontin, and the abundance of harmful bacteria including Duncaniella dubosii is reduced, thereby ultimately maintaining the homeostasis of intestinal flora, and overcoming the technical prejudice of the prior art regarding the use of osteopontin in maintaining the homeostasis of intestinal flora.

Methods for characterizing disease activity in a systemic lupus erythematosus (SLE) patient. Methods include obtaining a blood, serum, plasma, or urine sample from the patient; assessing the sample for expression of a biomarker selected from the group consisting of IFN-α, IL-10, BLyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4; assessing the sample for expression of an inflammatory mediator selected from the group consisting of TNFRII, Resistin, and Osteopontin (OPN); assessing the sample for an SLE-associated autoantibody specificity biomarker selected from the group consisting of dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP; and calculating a Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score may distinguish between active and low lupus disease activity. Methods of treatment are also provided including administering a treatment prior to reaching clinical disease classification after determining that the patient has the prognosis for transitioning to classified SLE.

The present invention relates to compositions comprising osteopontin (OPN) for the treatment and / or prevention of viral infections in mammals, such as humans, in particular infants, young children and pre-schoolers.

This invention relates to a combination comprising effective amounts of osteopontin and lactoferrin, for use in promoting the socio-emotional development of young individuals. The invention also relates to compositions and methods for promoting the socio-emotional development of young individuals, preferably infants.